ERIN LADD: Open Payments
NPI 1962092502 · GOLDEN, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,527 in 66 payments from 15 companies in 2025. Trend: 2023 $58 · 2024 $335 · 2025 $1,527
Food & beverage: $1,527
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $403 |
| Alkermes, Inc. | 8 | $375 |
| Supernus Pharmaceuticals, Inc. | 11 | $233 |
| Otsuka America Pharmaceutical, Inc. | 11 | $160 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $74 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Indivior Inc. | 2 | $37 |
| PFIZER INC. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
Products named: VRAYLAR, Qelbree, ARISTADA, REXULTI, LYBALVI, CAPLYTA, VIVITROL, Jornay PM.
Industry payments across CO — which companies pay providers there.
